Clinical Trial Update: WR 279,396 Open Label Treatment Protocol in Tunisia [Phase 2]

View source ↗

Summary

Phase 2 open-label study of WR 279,396 for cutaneous leishmaniasis in Tunisia was terminated, with results posted in December 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• WR 279,396

Snippet

Sponsor: U.S. Army Medical Research and Development Command | Conditions: Cutaneous Leishmaniasis | Phase 2 | Status: TERMINATED | Results posted: 2014-12-19